He Qingfang, Wang Lixin, Fang Yujia, Liang Mingbin, Chen Xiangyu, Hu Ruying, Zhong Jieming
Zhejiang Provincial Center for Disease Control and Prevention, No. 3399 Binsheng Road, Hangzhou, 310051, China.
Sci Rep. 2025 Jun 4;15(1):19500. doi: 10.1038/s41598-025-03133-1.
To evaluate the relationship of serum small dense low-density lipoprotein cholesterol (sdLDL-C) level with pre-diabetes (PD) and newly detected type 2 diabetes (NT2D) in a Chinese adults population, a cross-sectional study was conducted in 2022 from May 26 to September 17. Permanent residents at the age of 30-69 years who lived in two communities in Zhejiang Province, China, and participated in a community health checkup were selected as the survey objects. According to their fasting plasma glucose and glycosylated hemoglobin, the eligible subjects were divided into normal blood glucose group, PD group, and NT2D group. Logistic regression model was used to explore the effect of sdLDL-C level on PD and NT2D, and restricted cubic spline (RCS) was adopted to display the nonlinear dose-response relationship of sdLDL-C with the prevalence of PD and NT2D. A total of 3570 subjects were included with a median age of 58 (52, 64) years, and 58.7% (2097) were women. The prevalence of PD was 53.6% (1913 cases), and NT2D was 9.2% (327 cases). Logistic regression analysis showed that after controlling the confounding factors (including LDL-C), for every 0.1 mmol/L increase in sdLDL-C, the risk of developing PD and NT2D increased by 3.4% (OR = 1.034, 95%CI:1.002-1.067) and 15.7% (OR = 1.157, 95%CI: 1.097-1.220), respectively. The RCS curves showed that with the increase of sdLDL-C, both the risk of PD (P = 0.037) and NT2D (P < 0.001) increased, but there were no nonlinear dose-response relationships between sdLDL-C with PD (P for non-linearity = 0.142) and NT2D (P for non-linearity = 0.227). Subjects are at increased risk of PD and NT2D with increase of serum sdLDL-C level. sdLDL-C is a promising risk factor for PD and NT2D independent of LDL-C.
为评估中国成年人群血清小而密低密度脂蛋白胆固醇(sdLDL-C)水平与糖尿病前期(PD)及新诊断2型糖尿病(NT2D)的关系,于2022年5月26日至9月17日进行了一项横断面研究。选取居住在中国浙江省两个社区、年龄在30 - 69岁且参加社区健康体检的常住居民作为调查对象。根据空腹血糖和糖化血红蛋白,将符合条件的受试者分为正常血糖组、PD组和NT2D组。采用Logistic回归模型探讨sdLDL-C水平对PD和NT2D的影响,并采用限制立方样条(RCS)展示sdLDL-C与PD和NT2D患病率的非线性剂量反应关系。共纳入3570名受试者,中位年龄为58(52,64)岁,女性占58.7%(2097名)。PD患病率为53.6%(1913例),NT2D患病率为9.2%(327例)。Logistic回归分析显示,在控制混杂因素(包括低密度脂蛋白胆固醇)后,sdLDL-C每升高0.1 mmol/L,发生PD和NT2D的风险分别增加3.4%(OR = 1.034,95%CI:1.002 - 1.067)和15.7%(OR = 1.157,95%CI:1.097 - 1.220)。RCS曲线显示,随着sdLDL-C升高,PD(P = 0.037)和NT2D(P < 0.001)的风险均增加,但sdLDL-C与PD(非线性P = 0.142)和NT2D(非线性P = 0.227)之间均不存在非线性剂量反应关系。血清sdLDL-C水平升高会增加受试者发生PD和NT2D的风险。sdLDL-C是独立于低密度脂蛋白胆固醇的PD和NT2D的一个有前景的危险因素。